Jude Onyia

Jude Onyia

Chief Tech/Sci/R&D Officer at NEUROCRINE BIOSCIENCES, INC.

Net worth: 4 M $ as of 30/06/2026

62 year
Health Technology
Consumer Services

Profile

Currently, Jude Onyia is Director at Voyager Therapeutics, Inc. since 2023 and Chief Scientific Officer at Neurocrine Biosciences, Inc. since 2021.
Formerly, Dr. Onyia was Vice President-Biotechnology Discovery Research at Eli Lilly & Co. from 2014 to 2021 and Chief Scientific Officer at Capsida Biotherapeutics, Inc. in 2021.
Education includes a doctorate from State University of New York at Downstate Medical Center, an undergraduate degree from Suny College of Environmental Science & Forestry, and a doctorate from SUNY Upstate Medical University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
05/06/2026 23,405 ( 0.02% ) 4 M $ 30/06/2026
09/06/2026 2,910 ( 0% ) 10 185 $ 30/06/2026

Jude Onyia active positions

CompaniesPositionStart
NEUROCRINE BIOSCIENCES, INC. Chief Tech/Sci/R&D Officer 30/11/2021
VOYAGER THERAPEUTICS, INC. Director/Board Member 21/02/2023

Former positions of Jude Onyia

CompaniesPositionEnd
Chief Tech/Sci/R&D Officer 01/11/2021
ELI LILLY AND COMPANY Corporate Officer/Principal 01/06/2021
See the detail of Jude Onyia's experience

Training of Jude Onyia

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

79

1st degree connections

7

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies7

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology